We could not find any results for:
Make sure your spelling is correct or try broadening your search.
EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its October 8, 2024 annual general meeting of...
Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director Canada NewsWire EDMONTON, AB, May 30, 2024...
Quest Receives Cash Dividend Payment from OncoQuest Canada NewsWire EDMONTON, AB, Jan. 30, 2024 EDMONTON, AB, Jan. 30, 2024 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the...
Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits Canada...
Quest PharmaTech Provides Corporate Update Canada NewsWire EDMONTON, AB, Sept. 13, 2023 EDMONTON, AB, Sept. 13, 2023 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the...
Quest PharmaTech Announces Results from AGM Canada NewsWire EDMONTON, AB, July 14, 2023 EDMONTON, AB, July 14, 2023 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the...
Quest PharmaTech Provides Product Development Update Canada NewsWire EDMONTON, AB, July 10, 2023 EDMONTON, AB, July 10, 2023 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the...
Quest PharmaTech Provides Corporate Update Canada NewsWire EDMONTON, AB, June 9, 2023 TSX Venture: QPT EDMONTON, AB, June 9, 2023 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT...
L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - QPT Canada NewsWire VANCOUVER, BC, le 7 juin 2023 VANCOUVER, BC, le 7 juin 2023...
Canadian Investment Regulatory Organization Trade Resumption - QPT Canada NewsWire VANCOUVER, BC, June 7, 2023 VANCOUVER, BC, June 7, 2023 /CNW/ - Trading resumes in: Company: Quest PharmaTech...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions